The biological problem the index addresses is the defining paradox of Kawasaki disease. The illness presents as a feverish, inflammatory condition of childhood, with mucocutaneous signs such as cracked lips, conjunctival injection, rash and swollen lymph nodes, yet its most consequential damage is vascular. In the acute phase, a diffuse inflammatory process targets the medium-sized arteries, and the coronary arteries are particularly vulnerable. When inflammation weakens the arterial wall, the vessel can dilate into an aneurysm, a lesion that may regress over time or persist for life, setting the stage for stenosis, thrombosis and ischemic heart disease decades later. Intravenous immunoglobulin, given within the first ten days of illness, dramatically reduces this risk, but a meaningful fraction of children still develop coronary abnormalities, and some fail to respond to first-line therapy at all. Identifying those children early, ideally at the first encounter, is the goal of every risk-stratification effort in the field.

Current practice relies on a patchwork of tools. The American Heart Association, in its 2024 scientific statement on the diagnosis and management of Kawasaki disease, emphasizes echocardiographic surveillance and clinical judgment, and standardized Z-score formulas are used to express a child’s coronary artery dimensions relative to body surface area, allowing clinicians to distinguish dilation from aneurysm and to track progression. Predictive models have also been developed, including a widely discussed risk model validated in a North American population by Son and colleagues, which combines demographic and laboratory variables to estimate aneurysm probability before treatment begins. Saad and colleagues themselves have contributed to this effort, publishing a predictive modeling approach for early risk stratification in Pediatric Research earlier in 2026. Yet each tool has limitations: models built in one population may not transfer to another, Z-scores depend on accurate imaging and appropriate formula selection, and no single laboratory value has proven sufficiently discriminating on its own.

Into this gap steps the Aggregate Index of Systemic Inflammation. The AISI belongs to a family of composite inflammatory cell indexes that have attracted growing attention across medicine because they can be derived at no additional cost from parameters already reported on every differential blood count. In its standard formulation, the index multiplies the platelet count, the neutrophil count and the monocyte count, and divides by the lymphocyte count. Each component captures a facet of the inflammatory response: neutrophils and monocytes are the cellular vanguard of innate inflammation, platelets are acute-phase reactants whose numbers climb as interleukin-6 drives thrombopoiesis, and lymphocytes tend to fall under the suppressive weight of stress hormones and inflammatory cytokines. A high AISI therefore reflects a convergence of myeloid activation, thrombocytosis and relative lymphopenia, a pattern that in many diseases tracks the intensity of systemic inflammation more faithfully than any single cell line.

The appeal of such an index in Kawasaki disease is grounded in the disease’s own biology. Recent reviews, including a 2024 analysis in Nature Reviews Rheumatology by Noval Rivas and colleagues, have highlighted platelets not as passive bystanders but as active mediators of vascular inflammation in the illness. Platelets interact directly with activated endothelium, release pro-inflammatory and pro-thrombotic mediators, and contribute to the remodeling of the vessel wall that underlies aneurysm formation. Neutrophils, meanwhile, have been implicated in endothelial injury through the release of neutrophil extracellular traps, and monocytes infiltrate the inflamed arterial wall. The idea that a product of these very cell counts might correlate with coronary outcomes is therefore not a statistical accident in search of a mechanism; it is a hypothesis with a plausible pathophysiological backbone. The same logic has propelled AISI research in adult cardiovascular medicine, where a 2024 retrospective study in the Journal of Inflammation Research reported associations between the index and clinical outcomes in patients with acute myocardial infarction.

The immediate trigger for the commentary is a study by Liu, Peng and Zhou, published online in Pediatric Research in September 2026, which examined the association between the AISI and coronary artery aneurysm in patients with Kawasaki disease. That investigation reported that a higher AISI was associated with the presence of coronary artery aneurysm, suggesting that the index could help identify children who require closer coronary surveillance. Saad and his co-authors, writing from institutions spanning Egypt, Jordan, Russia, Saudi Arabia, the United Kingdom and Pakistan, use their commentary to appraise what this finding means for practice. Their assessment, summarized in the article’s impact statements, is measured: the AISI may serve as an additional inflammatory marker for identifying children with Kawasaki disease who need closer coronary monitoring, and AISI-based risk stratification may ultimately contribute to personalized approaches in disease management.

The commentary’s caution is as instructive as its enthusiasm. The authors state plainly that current evidence supports further prospective validation before the AISI can be included in treatment decision pathways. This is a crucial distinction in pediatric cardiology, where treatment intensification, such as the addition of corticosteroids or other adjunctive agents for high-risk children, carries its own risks and where misclassifying a low-risk child as high-risk can expose an infant to unnecessary immunosuppression. A retrospective association, however biologically plausible, does not establish that the index adds predictive information beyond what is already captured by age, sex, days of fever at diagnosis, baseline laboratory values and serial echocardiography. Establishing incremental value requires prospective cohorts, ideally across multiple populations, in which the AISI is measured at diagnosis and tested against coronary outcomes in models that already include established predictors.

Several technical considerations will shape that validation. The AISI’s components are not static: platelet counts in Kawasaki disease typically rise in the second week of illness, so the timing of the blood draw relative to fever onset materially changes the value. Thrombocytosis may be absent in the first days, precisely when treatment decisions must be made, which raises the question of whether an early AISI retains discriminative power. Related composite indexes built from the same count, such as ratios pairing platelets, neutrophils or monocytes with lymphocytes, have been studied in other inflammatory and surgical settings, and head-to-head comparisons would clarify whether the full four-component product offers genuine added sensitivity. Albumin, a negative acute-phase reactant that has been linked to coronary lesion progression in retrospective cohorts, and other conventional markers such as C-reactive protein, provide further benchmarks against which any new index must prove itself. Standardization of cutoffs, which vary across studies and populations, is another unresolved hurdle.

The broader significance of the commentary lies in its vision of low-cost, widely accessible risk stratification. The complete blood count is among the cheapest and most universally available tests in medicine, including in the low- and middle-income settings where Kawasaki disease is often diagnosed late and where advanced imaging may be scarce. An index that extracts additional prognostic information from data already in hand, without new reagents, equipment or expense, aligns squarely with the needs of global pediatric practice. If prospective studies confirm that the AISI meaningfully refines aneurysm risk prediction, it could be incorporated into the early triage of children at diagnosis, flagging those who warrant intensified anti-inflammatory therapy, more frequent echocardiography or referral to specialized centers. Conversely, if validation fails, the episode will still have sharpened the field’s understanding of how cellular inflammation relates to coronary pathology.

For now, the message from Saad and colleagues is one of disciplined optimism. The Aggregate Index of Systemic Inflammation is not a new test but a new lens on an old one, and its candidacy in Kawasaki disease rests on a coherent mechanistic rationale and an emerging body of evidence rather than on settled proof. The authors declare no competing interests and received no external funding for the commentary, and they frame the index explicitly as a potential complement to, not a substitute for, established clinical and echocardiographic assessment. Children with Kawasaki disease will continue to be managed according to current guidelines, with intravenous immunoglobulin, aspirin and serial coronary imaging. But the commentary signals that the next chapter of aneurysm risk prediction may be written not with expensive biomarkers or novel imaging, but with a few numbers multiplied together from a blood count that every febrile child already receives.

Subject of Research: Evaluation of the Aggregate Index of Systemic Inflammation as a marker of coronary aneurysm risk in Kawasaki disease

Article Title: Inflammatory burden and coronary aneurysm risk in Kawasaki disease: appraising the Aggregate Index of Systemic Inflammation

Article References: Saad, K., Aly, S. E., Zeid, S. S. K., Ahmad, A. R., Elfarargy, M. S., Elkossi, M., Mumtaz, M. H., & Temsah, M.-H. (2026). Inflammatory burden and coronary aneurysm risk in Kawasaki disease: appraising the Aggregate Index of Systemic Inflammation. Pediatric Research. https://doi.org/10.1038/s41390-026-05590-4

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05590-4

Keywords: Kawasaki disease, coronary artery aneurysm, Aggregate Index of Systemic Inflammation, AISI, inflammation, pediatric cardiology, risk stratification, complete blood count, platelets, echocardiography, intravenous immunoglobulin, biomarkers

The research, conducted by Junxiu Liu of the Department of Child Health Care at Qianjiang Central Hospital of Chongqing, Yue Peng of the Department of Cardiovascular Medicine at the Children’s Hospital of Chongqing Medical University, and Dan Zhou of the Department of Respiratory Medicine at Qianjiang Central Hospital of Chongqing, enrolled 345 consecutive children with Kawasaki disease and examined them during the acute phase of illness. Among this cohort, 64 patients went on to develop a coronary artery aneurysm, a rate that reflects the stubborn reality that even with standard intravenous immunoglobulin therapy, a meaningful minority of affected children still sustain vascular injury. The team’s goal was not to invent a new biomarker from scratch but to test whether a composite index derived from ordinary laboratory parameters could outperform intuition and serve as a practical risk stratification instrument.

The Aggregate Index of Systemic Inflammation, commonly abbreviated AISI, is calculated by multiplying the neutrophil, platelet, and monocyte counts and dividing the product by the lymphocyte count. Each of these cellular components captures a different facet of the inflammatory response that defines Kawasaki disease. Neutrophils rise early in the illness and are implicated in the degradation of the extracellular matrix that weakens arterial walls; monocytes and their derived macrophages infiltrate the coronary vasculature and fuel the vasculitis at the heart of the disease; platelets surge in the convalescent phase and participate in the endothelial activation and prothrombotic state that characterize the disease’s vascular complications. Lymphocytes, by contrast, tend to be depleted during vigorous systemic inflammation, so a low lymphocyte count amplifies the index. By combining all four parameters, the AISI effectively integrates the intensity of innate immune activation, the prothrombotic tendency, and the immune dysregulation visible in a single routine blood draw.

Using univariable comparisons followed by multivariable logistic regression, the investigators identified three independent factors associated with coronary artery aneurysm formation. Younger age emerged as protective against the complication per unit increase in years, with an odds ratio of 0.980 and a 95 percent confidence interval of 0.966 to 0.985, a statistically significant association with a p value of 0.008. Lower serum albumin was also linked to aneurysm risk, with an odds ratio of 0.937 per unit increase and a confidence interval spanning 0.880 to 0.997, significant at p equal to 0.040. Albumin declines when inflammation becomes severe and vascular permeability increases, so hypoalbuminemia serves as a chemical mirror of inflammatory intensity and capillary leak. Most notably, the AISI itself, analyzed per 100-unit increment, carried an odds ratio of 1.045 with a 95 percent confidence interval of 1.003 to 1.089 and a p value of 0.036, indicating that each step up in the index independently raised the odds of an aneurysm even after accounting for age and nutritional markers.

To translate the continuous index into a clinically usable threshold, the team performed an exploratory analysis that yielded a cutoff value of 711.58. When the cohort was divided at this point into a low AISI group and a high AISI group, the difference in outcomes was striking: children in the high AISI group experienced coronary artery aneurysms at a significantly higher rate than those in the low AISI group, with a p value below 0.001. In practical terms, this means a pediatrician staring at a standard complete blood count on the day of admission could compute the index, compare it against the exploratory threshold, and obtain an early, data-driven estimate of the child’s likelihood of developing coronary involvement before echocardiographic changes become apparent.

The biological plausibility of the finding rests on the pathogenesis of Kawasaki disease itself. The condition is an acute, systemic vasculitis that preferentially targets medium-sized arteries, and the coronary arteries are particularly vulnerable, especially in infants and toddlers. Histopathological studies have long described panvasculitis with edema of the intima, infiltration of inflammatory cells, and fragmentation of the internal elastic lamina, processes that together permit the outward expansion of the vessel wall into an aneurysm. Oxidative stress, endothelial dysfunction, and platelet-mediated vascular inflammation have all been implicated in the progression from acute inflammation to structural arterial damage. Because neutrophils, monocytes, and platelets each participate in these cascades, a composite index that multiplies their concentrations provides a running tally of the inflammatory and thrombotic forces acting on the coronary wall, whereas lymphopenia signals the severity of the systemic immune disturbance.

The study builds on a growing literature linking derived inflammatory indices to cardiovascular outcomes in adult medicine. The AISI and its cousins, such as the systemic immune-inflammation index and the systemic inflammation response index, have been associated with clinical outcomes in acute myocardial infarction, with coronary artery calcification, with acute coronary syndrome in patients with and without diabetes, and with all-cause and cardiovascular mortality in female cancer patients, and the index has even been proposed as a predictor of mortality in stroke. Extending this framework to pediatric vasculitis represents a conceptual bridge: the same arithmetic that quantifies inflammatory burden in adult atherosclerotic disease may also capture the vasculitic intensity that drives coronary dilatation in children. Previous risk models for coronary aneurysms in Kawasaki disease, including a validated North American risk score, have relied on combinations of demographic, clinical, and laboratory variables; the appeal of the AISI lies in its simplicity and its availability at no additional cost.

The clinical implications, according to the authors, are potentially significant. The study’s impact statement notes that early identification based on the Aggregate Index of Systemic Inflammation may assist clinicians in implementing more aggressive treatment strategies, such as intravenous immunoglobulin combined with corticosteroids, thereby improving outcomes for Kawasaki disease patients. This matters because the standard regimen of intravenous immunoglobulin and aspirin fails to prevent coronary aneurysms in a substantial fraction of patients, and children who resist the first dose face difficult decisions about second-line agents, including repeat immunoglobulin, infliximab, or corticosteroids. Trials such as the KIDCARE study, which compared infliximab with a second dose of intravenous immunoglobulin in resistant cases, have refined the therapeutic arsenal, but those agents are typically deployed only after treatment failure is evident. A biomarker available on day one that flags high-risk children could shift that decision earlier, before the vascular injury has begun to accrue, which is precisely the window in which intensified therapy is believed to be most effective.

The authors are careful to frame their findings within the study’s design. The work was retrospective, drawing on records from consecutive patients at their institutions, and the cutoff of 711.58 is explicitly described as exploratory, meaning it will require validation in independent, ideally prospective, and ethnically diverse cohorts before it can be embedded in clinical guidelines. Albumin and age also entered the final model, suggesting that the AISI is best understood as one component of a broader risk picture rather than a stand-alone verdict. Nevertheless, the strength of the association, the significance across multiple independent variables, and the stark difference in aneurysm rates between high and low index groups give the finding real weight. The datasets generated in the study are available from the corresponding author on reasonable request, and the work was approved by the hospital’s Research Ethics Committee with waived informed consent, with no competing interests declared.

For a disease that was first described more than half a century ago and that continues to puzzle researchers with an unclear cause, the prospect of extracting actionable risk information from a routine blood count is a reminder that progress does not always require new molecules or expensive assays. Sometimes it requires looking harder at the data already in hand. If future validation confirms the exploratory threshold identified by Liu, Peng, and Zhou, the Aggregate Index of Systemic Inflammation could become a standard part of the acute Kawasaki disease assessment, helping clinicians worldwide decide within hours which febrile child needs the most aggressive anti-inflammatory therapy, and which can be managed with confidence under the conventional regimen. In the meantime, the study adds Kawasaki disease to the expanding list of inflammatory cardiovascular conditions for which a four-cell arithmetic snapshot of the immune system carries genuine prognostic power.

Subject of Research: The association between the Aggregate Index of Systemic Inflammation and coronary artery aneurysm formation in children with acute Kawasaki disease.

Article Title: Association of the Aggregate Index of Systemic Inflammation with coronary artery aneurysm in Kawasaki disease patients

Article References: Liu, J., Peng, Y., & Zhou, D. (2026). Association of the Aggregate Index of Systemic Inflammation with coronary artery aneurysm in Kawasaki disease patients. Pediatric Research. https://doi.org/10.1038/s41390-026-05500-8

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05500-8

Keywords: Kawasaki disease, coronary artery aneurysm, Aggregate Index of Systemic Inflammation, AISI, pediatric cardiology, vasculitis, inflammation biomarker, complete blood count, intravenous immunoglobulin, serum albumin, risk prediction, children